Tiziana Life Sciences has been granted a patent for a method to treat myelodysplastic syndrome (MDS) and cancer using dactinomycin delivered via nanoparticles. The composition includes specific characteristics like PLA-mPEG encapsulation and size range for effective treatment. GlobalData’s report on Tiziana Life Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Tiziana Life Sciences, Cancer treatment biomarkers was a key innovation area identified from patents. Tiziana Life Sciences's grant share as of May 2024 was 15%. Grant share is based on the ratio of number of grants to total number of patents.
Nanoparticle delivery of dactinomycin for treating myelodysplastic syndrome
A recently granted patent (Publication Number: US11975111B2) discloses a method for treating myelodysplastic syndrome (MDS) by administering a composition containing dactinomycin encapsulated in nanoparticles comprising PLA-mPEG. The composition, when administered to a subject in need, results in a specific concentration range of dactinomycin in the subject's system, aiding in the treatment of MDS. The nanoparticles have a defined size range of 100 nm to 200 nm, with the PLA-mPEG composition containing about 25% mPEG by weight and a molecular weight of approximately 30,000 Da.
Furthermore, the patent claims include the addition of a surfactant, specifically polyvinyl alcohol, to the composition. The composition may contain dactinomycin in the range of 5% to 15% by weight. Additionally, the method allows for the inclusion of other chemotherapeutic drugs alongside dactinomycin, such as topoisomerase inhibitors, platinum-based therapies, anthracycline antibiotics, taxanes, tyrosine kinase inhibitors, nucleoside analogs, FLT3 inhibitors, and hypermethylation inhibitors. The molar ratio of these additional drugs to dactinomycin can vary within specified ranges, providing flexibility in treatment options for MDS patients.
To know more about GlobalData’s detailed insights on Tiziana Life Sciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
